Jonathan Steckbeck is an entrepreneur and the founder and CEO of Peptilogics. Jonathan founded Peptilogics to develop and commercialize novel anti-infective strategies to address the impending antibiotic resistance crisis, one of the greatest threats to modern medicine and public health and safety. He has led Peptilogics’ development into a capital-efficient clinical-stage biopharmaceutical company. Jonathan has a long history in working to combat infectious diseases, with a broad early focus on HIV vaccine development. For the last 12 years he has been focused on understanding and developing novel strategies to deal with the threat from antibiotic resistant bacteria.
Jonathan holds a BS in Microbiology from The Pennsylvania State University, an MBA in Business Strategy from the Katz Graduate School of Business at the University of Pittsburgh, and a PhD in Biochemistry from the University of Pittsburgh School of Medicine.